Giredestrant plus everolimus reduced the risk of disease progression or death by 44% and 62% in ITT and ESR1-mutated populations, respectively, in a post-CDK inhibitor setting, compared with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback